You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
2-HOBA for Treatment of Pulmonary Hypertension
SBC: MTI Biotech Incorporated Topic: NHLBIPROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Implantable Microarray Probe for Real-Time Glutamate and GABA Detection
SBC: ALCORIX CO Topic: 105Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
MRI Virtual Pathology of the Prostate: Multi-center multi-vendor application and validation
SBC: QMIS Topic: 102PROJECT SUMMARY The U.S. Preventative Task Force found current ultrasound-based screening methods unreliable, causing unnecessary biopsies and failing to detect clinically significant Prostate Cancer (PCa) in patients with an elevated prostate-specific antigen (PSA). Millions of men in the U.S. alone are currently at elevated risk for PCa, but there are no effective alternatives for screening. Alt ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing an app-based behavioral intervention to help depressed individuals return to work
SBC: INSPIRATION AT WORK INC Topic: 104PROJECT SUMMARY Significance: The overarching goal of this proposal is to develop an intervention to help unemployed individuals with major depressive disorder (MDD) return to work. Individuals who lose their jobs are at risk for MDD and other psychiatric disorders. Because a core feature of MDD is decreased motivation, unemployed individuals with MDD can enter a `vicious cycle' where their depres ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA genome, which can cause seasonal or pandemic flu with high morbidity and significant mortality. Vaccination is the most prevalent prophylactic means for controlling influenza infections. However, an effective vaccine usually takes at least six months to develop. Furthermore, vaccination has limited ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics
SBC: Neurolux, Inc. Topic: 101Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biol ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission
SBC: EDEN PARK ILLUMINATION, INC. Topic: NIAIDDrug resistant bacteria such as MRSA, and airborne-transmitted microbes such as influenza and TB, present significant health issues, with major healthcare and economic consequences. UV light is a well-established highly-efficient anti-microbial modality, effective both against both bacteria and viruses. However it is not possible to use UV sterilization in scenarios where people are present becaus ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a peptide-based oral drug to prevent kidney stones
SBC: Oxalo Therapeutics, Inc. Topic: 400Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
4-(Aminomethyl) benzamides as novel anti-Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
An Automated Patient Chart Error Detection System for Radiation Therapy
SBC: Infondrian LLC Topic: 101Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health